e-learning
resources
Virtual 2020
Pre-Congress Content
Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis
H. Jessen (Herlev, Denmark), N. Hoyer (Copenhagen, Denmark), S. Rønnow (Herlev, Denmark), M. Karsdal (Herlev, Denmark), D. Leeming (Herlev, Denmark), J. Sand (Herlev, Denmark), S. Shaker (Copenhagen, Denmark)
Source:
Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Session:
Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Session type:
E-poster session
Number:
734
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Jessen (Herlev, Denmark), N. Hoyer (Copenhagen, Denmark), S. Rønnow (Herlev, Denmark), M. Karsdal (Herlev, Denmark), D. Leeming (Herlev, Denmark), J. Sand (Herlev, Denmark), S. Shaker (Copenhagen, Denmark). Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis. 734
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Extracellular matrix profile of lung in idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Increased polysialylation in lung tissue of patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - Cell biology of lung disease
Year: 2011
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: Eur Respir J 2011; 37: 1119-1127
Year: 2011
Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (3) 00019-2016; 10.1183/23120541.00019-2016
Year: 2017
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Difference in the dynamic state between SP-A and SP-D in the IPF lung
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Role of endothelin in lung fibrosis
Source: Eur Respir Rev 2008; 17: 145-150
Year: 2008
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Novel CT markers of volume loss in idiopathic pulmonary fibrosis (IPF) predict mortality
Source: International Congress 2017 – Novel imaging findings characterising various lung diseases and their prognoses
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept